Videos:2017 Kidney Cancer Association Patient & Survivor Conference
Conclusions.01/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 9, 2018 Category: Urology & Nephrology Source Type: news

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."01/02/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 22, 2017 Category: Urology & Nephrology Source Type: news

U.S. FDA Approval of CABOMETYX ® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.12/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2017 Category: Urology & Nephrology Source Type: news

NICE recommends Eisai ’s Kisplyx for renal cell carcinoma
Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.12/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2017 Category: Urology & Nephrology Source Type: news

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer
The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...12/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2017 Category: Urology & Nephrology Source Type: news

Dr. Escudier: The Future of RCC Treatment
Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. He is a member of the Kidney Cancer Association Professional Group and formerly a member of its Medical& Scientific Steering Committee. His research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutics.12/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 7, 2017 Category: Urology & Nephrology Source Type: news

Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes
In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC.12/06/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 6, 2017 Category: Urology & Nephrology Source Type: news

“I need to go to the doctor,” Quiet 5-year-old girl knew something was wrong
Reese Park is working toward a day with no training wheels outside her Bridge Creek home. The 5-year-old is biking with her siblings, which includes quite a crew since she's the second oldest of six children. Reese's parents describe her as strong and quiet, so she seemed very out of character last July when she told her dad she needed medical help right away.12/06/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 6, 2017 Category: Urology & Nephrology Source Type: news

FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.11/30/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 19, 2017 Category: Urology & Nephrology Source Type: news